asco 2005 gynecologic oncology markpap® test for cervical ...to
TRANSCRIPT
![Page 1: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/1.jpg)
1
ASCO 2005Gynecologic Oncology
MarkPap® Test for Cervical Cancer Screening
N.S. Markovic, O. Markovic, E.S. Henderson,
BioSciCon’s Cervical Cancer Study Group*
![Page 2: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/2.jpg)
2
*BioSciCon’s Cervical Cancer Study Group
• Markovic Nenad, BioSciCon, Rockville, MD• Markovic Olivera, BioSciCon• Shelley Parr, UMD Health Center, College Park, MD• Alan Ross, Women’s Health Care Center, Bethesda, MD• Rufus Rosser, Ob/Gy Off., Laurel, MD, Washington, DC• Lewis Townsend, Contemporary Women Health Care
Associates, Bethesda, MD• Jed Gould, Ob/Gy Offices, Laurel, Bethesda,
Gaithersburg, MD• James Sundeen, Diagnostic Pathology Services,
Clarksburg, MD• William Smith, Jr. & Aruna Kumar, Pathology, Suburban
Hospital, Bethesda, MD. • Shiniwas Katti, consultant-statistician.
![Page 3: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/3.jpg)
3
Background
At ASCO 2001, we introduced a new biomarker-driven technology for improving the visualization of epithelial cells with abnormalities on Pap smears. The biomarker was cervical acid phosphatase labeling dysplastic cells.
At ASCO 2004, we presented data of two clinical trials.
This time, we are presenting results of comparing the new test with the conventional Pap smear in general population (GP).
![Page 4: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/4.jpg)
4
MarkPap® Test
• MarkPap® Test (BioSciCon, Rockville, MD) is a double-staining, single slide cytological method for demonstration of cervical acid phosphatase inside Papanicolaou stained abnormal cervical cells on smears or monolayers prepared from specimens collected in solution.
• The test is available from the manufacturer, the Ricca Chemical Company, Arlington, TX.
![Page 5: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/5.jpg)
5
Cervical acid phosphatase (CAP)
• Cervical acid phosphatase is visualized as red, granular deposit inside cells counterstained with a modified Papanicolaou technique (Fig. 1-4)
• The red biomarker is clearly visible on the bluish background of cervical cells.
• This visual characteristics reduce the probability for omission of labeled cells.
![Page 6: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/6.jpg)
6
Fig. 1: ASC-H (x20)
CAP labels 3 small abnormal cells
x20
NormalCAP
Negative cells
![Page 7: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/7.jpg)
7
Fig. 2: ASC-H (x100)
x100
CAP is the red marker
NormalCAP
negativecell
![Page 8: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/8.jpg)
8
Fig. 3: LSIL (x100)
HPV cells
Red biomarker
Bi-nucleus
Micro-vacuolalization
Dyskaruosis
Koilocyte-like cells
![Page 9: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/9.jpg)
9
Biomarker: Advantage for cervical cancer screening
• Cervical acid phosphatase (CAP) in cervical squamous cells is a biomarker for cervical dysplasia and HPV infection.
• CAP is positive in more than 99.98% cervical abnormal cells.
• CAP is negative in more than 99.99% normal cervical squamous cells.
![Page 10: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/10.jpg)
10
MarkPap Utilization: Hypotheses tested
• If this biomarker enhances the detection of abnormal cervical cells, how this can be utilized for cervical cancer screening?
• If MarkPap (CAP+PAP) is superior to PAP, is the difference meaningful to replace PAP?
• Is the difference [MarkPap-PAP] higher than 30% in General Population (GP) of women coming for regular Pap test
• Ho: πe < πs + δ (0.3 πs )
• HA :πe ≥ πs + δ (0.3 πs )
![Page 11: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/11.jpg)
11
Study Design
• Multicenter, split-sample (case-control) study, intended:
• To assess the efficacy of cytoscreeners using MarkPap to improve the detection of abnormal cervical specimens, and
• To reduce the false negative readings, in comparison with those using the control Pap smear.
• Measuring endpoints: proportion, sensitivity, specificity, predictive values, false negative rates.
![Page 12: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/12.jpg)
12
Clinical Trial: GP - 1
Population• N = 1,067 women age
18 and above who came to doctor’s offices for regular Pap test.
• Prerequisite: • Confirmed eligibility• Signed Informed
Consent
Specimens• Collected 2,150 at 8
clinical sites• Analyzed for control
Pap smear (PAP) and new test (MarkPap) in a single contract research laboratory (DPS, Clarksburg, MD)
![Page 13: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/13.jpg)
13
Study ManagementCentral Research Site
• Design• Organization• Financing• Monitoring for
compliance• Monitoring for
adverse events• Data acquisition
• Data collection• Data base(s)• Data management• Data evaluation• Adjudication
• Statistical analyses• Study evaluation
![Page 14: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/14.jpg)
14
Specimen processing - Laboratory
Control smear• Receive, register,
code, label, assign to Pap test procedure.
• Stain with Papanicolaou stains using an automatic slide stainer
MarkPap smear• Receive, register,
code, label, assign to MarkPap test procedure.
• Process for marker visualization.
• Stain background with Papanicolaou stains
![Page 15: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/15.jpg)
15
Fig. 4 : Quality Control & Quality Assurance
COMBO control slide containing HeLa and buccal cells
HeLaCAP+
BuccalCAP[-]
![Page 16: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/16.jpg)
16
PAP Slide screening
Control slide• Primary screening:• Screen for epithelial
cell abnormalities and report using the Bethesda System terminology.
• All positive/abnormal slides rescreen for QC
• Ten percent negative/normal slides and slides from high-risk patients send for second opinion (QC).
• Send reports back to clinical sites and store into the study dbase.
![Page 17: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/17.jpg)
17
MarkPap slide screening
• MarkPap slide
• Primary screening: Screen for biomarker and for epithelial cell abnormalities.
• All positive/abnormal slides send for QC to pathologist
• All negative/normal slides send for QC to cytotechnologist
• Report results in the Laboratory dbase
![Page 18: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/18.jpg)
18
Post-study handling
• Decoding at the end of study
• Using dbase information, compare results of screening test and control slides.
• If results are associated, record this result as “true” value.
• If results are discrepant, send Pap slides for adjudication.
• Use adjudicated results as “true” values.
![Page 19: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/19.jpg)
19
Evaluation
• Validate results of the test and the control screening using “true” values.
• Calculate sensitivity and specificity of test and control results using “true” values as standard.
• Use 95%CI for improving the probability of assessment.
• Test hypothesis for equivalency Pe-Ps < δ (5%-50%)
• Test for significance of the difference using the McNemar test for comparison of proportions in paired groups
![Page 20: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/20.jpg)
20
Results
Pap smear• N= 947• TP = 21• TN = 898• Se: 0.46
• Sp: 0.99
MarkPap test• N= 947• TP = 38• TN = 858• Se: 0.84
• Sp: 0.95
![Page 21: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/21.jpg)
21
McNemar Test*
• (CPT+)(PAP+) = 15 (a)• (CPT+)(PAP-) = 139 (b)• (CPT-)(PAP+) = 51 (c)• (CPT-)(PAP-) = 855 (d)• ([b-c]-1)2 /(b+c) = 59.45 (1df)• 2-tailed P value = 0.0001• Odds ratio = 3.861• 95%CI: LL = 2.660, UL= 5.737 *QuickCalcs (www.graphpad.com)
![Page 22: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/22.jpg)
22
Predictive Values* *QuickCalcs (www.graphpad.com)
PAP control• Se: 46• Sp: 99• Prevalence: 7• PPV: 77
• NPV: 96• FN: 3.94
MarkPap test• Se: 84• Sp: 95• Prevalence: 7• PPV: 56
• NPV: 99• FN: 1.25
![Page 23: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/23.jpg)
23
Conclusion
• MarkPap test is superior to the PAP smear for:
• Detection of abnormal specimens
• Sensitivity of screening for cervical cancer
• Allows for less false negative readings
![Page 24: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/24.jpg)
24
Acknowledgment
• This work was supported in part by NIH-NCI SBIR Grant No. 1 R43 CA086767-01, and No. 2 R44 CA086767-02
• NCI, DCP, Biomarker Research Group
• MdBio and Dr. Charlie Grudzinskas
• University of Maryland IRB
![Page 25: ASCO 2005 Gynecologic Oncology MarkPap® Test for Cervical ...to](https://reader036.vdocuments.mx/reader036/viewer/2022081404/55999d1f1a28ab6b0d8b481f/html5/thumbnails/25.jpg)
25
Correspondence
• Nenad Markovic, M.D., Ph.D.• BioSciCon, Inc.• 14905 Forest Landing Circle• Rockville, MD 20850• Tel 301-610-9130• Fax 301-610-7662• E-mail: [email protected]